Indirect recognition of T-cell epitopes derived from the α3 and transmembrane domain of HLA-A2

American Journal of Transplantation

Volumn 7, Issue 5, 2007, Pages 1148-1157

  Hanvesakul, R ^a,b   Maillere, B ^c   Briggs, D ^d   Baker, R ^e   Larche M ^f,g   Ball, S ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CEA SACLAY   (France)

^d NHS BLOOD AND TRANSPLANT   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Alloantibody; Allorecognition; Epitope; Peptide

Indexed keywords

ALLOANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; MEMBRANE PROTEIN; T LYMPHOCYTE ANTIGEN;

ADULT; AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CELL ACTIVATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMPLEMENTARITY DETERMINING REGIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; GENES, MHC CLASS II; GRAFT REJECTION; HLA-A2 ANTIGEN; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 34247530370     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01743.x     Document Type: Article

References (49)

1. Rogers NJ, Lechler RI. Allorecognition. Am J Transpl 2001 1 : 97 102.
2. Benichou G, Takizawa PA, Olson CA, McMillan M, Sercarz EE. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med 1992 175 : 305 308.
3. Fangmann J, Dalchau R, Fabre JW. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J Exp Med 1992 175 : 1521 1529.
4. Sawyer GJ, Dalchau R, Fabre JW. Indirect T cell allorecognition: A cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens. Transpl Immunol 1993 1 : 77 81.
5. Vella JP, Magee C, Vos L et al. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation 1999 67 : 1523 1532.
6. Lovegrove E, Pettigrew GJ, Bolton EM, Bradley JA. Epitope mapping of the indirect T cell response to allogeneic class I MHC: sequences shared by donor and recipient MHC may prime T cells that provide help for alloantibody production. J Immunol 2001 167 : 4338 4344.
7. Sauve D, Baratin M, Leduc C, Bonin K, Daniel C. Alloantibody production is regulated by CD4+ T cells' alloreactive pathway, rather than precursor frequency or Th1/Th2 differentiation. Am J Transplant 2004 4 : 1237 1245.
8. Steele DJ, Laufer TM, Smiley ST et al. Two levels of help for B cell alloantibody production. J Exp Med 1996 183 : 699 703.
9. Vella JP, Spadafora-Ferreira M, Murphy B et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997 64 : 795 800.
10. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: Potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol 2002 13 : 252 259.
11. Ciubotariu R, Liu Z, Colovai AI et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998 101 : 398 405.
12. Reznik SI, Jaramillo A, SivaSai KS et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001 1 : 228 235.
13. SivaSai KS, Smith MA, Poindexter NJ et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999 67 : 1094 1098.
14. Hornick PI, Mason PD, Baker RJ et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000 101 : 2405 2410.
15. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001 167 : 7199 7206.
16. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003 75 : 1034 1040.
17. Yamada A, Chandraker A, Laufer TM et al. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001 167 : 5522 5526.
18. Kishimoto K, Yuan X, Auchincloss H, Jr., Sharpe AH, Mandelbrot DA, Sayegh MH. Mechanism of action of donor-specific transfusion in inducing tolerance: Role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol 2004 15 : 2423 2428.
19. Mirenda V, Berton I, Read J et al. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: An efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004 15 : 987 997.
20. Lagaaij EL, Hennemann IP, Ruigrok M et al. Effect of one-HLA-DR-antigen- matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989 321 : 701 705.
21. Roelen D, Brand A, Claas FH. Pretransplant blood transfusions revisited: A role for CD(4+) regulatory T cells? Transplantation 2004 77 (1 Suppl S26 S28.
22. Iacomini J, Sayegh MH. Measuring T cell alloreactivity to predict kidney transplant outcomes: Are we there yet? J Am Soc Nephrol 2006 17 : 328 330.
23. Frasca L, Tamir A, Jurcevic S et al. Peptide analogues as a strategy to induce tolerance in T cells with indirect allospecificity. Transplantation 2000 70 : 631 640.
24. Chen TC, Waldmann H, Fairchild PJ. Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. J Clin Invest 2004 113 : 1754 1762.
25. Jiang S, Camara N, Lombardi G, Lechler RI. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex-vivo. Blood 2003 102 : 2180 2186.
26. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005 11 (4 Suppl S69 S76.
27. Stegmann S, Muller A, Zavazava N. Synthetic HL A-A2 derived peptides are recognized and presented in renal graft recipients. Hum Immunol 2000 61 : 1363 1369.
28. Dankers MK, Roelen DL, Van Der Meer-Prins EM et al. Differential immunogenicity of HLA mismatches: HLA-A2 versus HLA-A28. Transplantation 2003 75 : 418 420.
29. Welsh KI, Bunce M. HLA typing, matching and crossmatching in renal transplantation. In : Morris PJ, eds. Kidney Transplantation, 5th Ed. Philadelphia : W. B. Saunders, 2001 : 135 158.
30. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 2002 74 : 1377 1381.
31. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005 16 : 2804 2812.
32. Tambur AR, Bray RA, Takemoto SK et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation 2000 70 : 1055 1059.
33. Texier C, Pouvelle S, Busson M et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000 164 : 3177 3184.
34. Texier C, Pouvelle-Moratille S, Busson M, Charron D, Menez A, Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3, -DRB4 and -DRB5 molecules. Eur J Immunol 2001 31 : 1837 1846.
35. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993 178 : 27 47.
36. Frasca L, Amendola A, Hornick P et al. Role of donor and recipient antigen-presenting cells in priming and maintaining T cells with indirect allospecificity. Transplantation 1998 66 : 1238 1243.
37. Watschinger B, Gallon L, Carpenter CB, Sayegh MH. Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation 1994 57 : 572 576.
38. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001 12 : 2500 2506.
39. Pettigrew GJ, Lovegrove E, Bradley JA, Maclean J, Bolton EM. Indirect T cell allorecognition and alloantibody-mediated rejection of MHC class I-disparate heart grafts. J Immunol 1998 161 : 1292 1298.
40. Valujskikh A, Fedoseyeva E, Benichou G, Heeger PS. Development of autoimmunity after skin graft rejection via an indirect alloresponse. Transplantation 2002 73 : 1130 1137.
41. Tam RC, Fedoseyeva EV, Moskalenko M, Garovoy MR, Benichou G. T cell tolerance is influenced by concomitant T cell recognition of cross-reactive self-peptides. J Immunol 1996 156 : 3765 3771.
42. Soares LR, Orr PL, Garovoy MR, Benichou G. Differential activation of T cells by natural antigen peptide analogues: Influence on autoimmune and alloimmune in vivo T cell responses. J Immunol 1998 160 : 4768 4775.
43. Nisco S, Vriens P, Hoyt G et al. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A. J Immunol 1994 152 : 3786 3792.
44. Chowdhury NC, Saborio DV, Garrovillo M et al. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Transplantation 1998 66 : 1059 1066.
45. Semiletova NV, Shen XD, Feldman DM, Busuttil RW, Kupiec-Weglinski JW, Ghobrial RM. Donor MHC class I peptides in conjunction with self-epitopes induce donor-specific tolerance in a dose-dependent manner but unable to abrogate chronic rejection. Transpl Proc 2005 37 : 1937 1939.
46. Bushell A, Karim M, Kingsley CI, Wood KJ. Pretransplant blood transfusion without additional immunotherapy generates CD25+CD4+ regulatory T cells: A potential explanation for the blood-transfusion effect. Transplantation 2003 76 : 449 455.
47. Magee CC, Azuma H, Knoflach A et al. In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. J Am Soc Nephrol 1999 10 : 1997 2005.
48. Boytim ML, Lilly P, Drouvalakis K et al. A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling. J Clin Invest 2000 105 : 1447 1453.
49. Zang W, Kalache S, Lin M, Schroppel B, Murphy B. MHC Class II-mediated apoptosis by a nonpolymorphic MHC Class II peptide proceeds by activation of protein kinase C. J Am Soc Nephrol 2005 16 : 3661 3668.